Endomyocardial Biopsy Market Report: Size, Share & Forecast

Endomyocardial Biopsy Market Report: Valuation Timeline 2024–2030

The global endomyocardial biopsy market is estimated at USD 365.3 million in 2024, with a projected expansion to USD 416.0 million in 2026 and USD 543.0 million by 2030, registering a CAGR of 6.9% from 2025 to 2030. North America remains the dominant region, capturing 43.0% of global revenue in 2024, while Asia-Pacific is poised for the fastest growth at 10.0% CAGR over the forecast period. This proprietary analysis integrates primary interviews across the value chain to deliver a granular, segment-level outlook.

Demand is underpinned by rising heart transplant volumes—over 31,238 transplants were performed in the U.S. over a decade per UNOS—and a growing burden of myocarditis and cardiomyopathy. The procedure remains the gold standard for graft rejection surveillance, with 60–65% of North American transplant patients undergoing at least one biopsy.

Forceps and Accessories: Core Product Revenue Dynamics

The forceps segment dominates the market with a 71.9% revenue share in 2024, driven by their indispensable role in tissue extraction. Precision-enhanced forceps, including coated maxi-curve designs, are witnessing elevated demand due to improved sampling accuracy and reduced complication risk. Key OEMs such as Argon Medical Devices and Cordis offer a broad portfolio tailored to diverse anatomical requirements.

The accessories segment is forecast to grow at a 6.3% CAGR, fueled by rising adoption of steerable catheters, guidewires, and stabilizing sheaths that enhance procedural safety and efficiency. Innovations in flexible needles and imaging-compatible accessories further support this growth trajectory.

• Forceps: Largest revenue contributor; high adoption in transplant surveillance.
• Accessories: Fastest-growing; driven by integration with image-guided systems.
• Customization: Modular kits and disposable variants gain traction in ambulatory settings.

Straight and Pre-Curved Tip Segments: Precision at the Point of Care

The straight tip segment held the largest share at 36.2% in 2024, favored for initial puncture and navigation due to its precision and minimal tissue damage risk. However, the pre-curved segment is expected to expand at a 7.3% CAGR, as its flexibility facilitates access to complex cardiac anatomies and reduces the learning curve for clinicians.

Emerging evidence from our primary interviews indicates that pre-curved tips are increasingly preferred in Asia-Pacific centers adopting minimally invasive techniques, contributing to the region's rapid growth.

Hospital and Ambulatory Surgery Center End-Use Adoption

Hospitals commanded a 51.5% revenue share in 2024, supported by high transplant volumes and comprehensive post-transplant care pathways. The growing number of hospitals globally, particularly in emerging economies, is expected to sustain this dominance. Ambulatory surgery centers (ASCs) are projected to grow at a 6.0% CAGR, as patients increasingly opt for cost-effective, convenient alternatives. Technological advancements now allow safe and effective EMB procedures in ASC settings, reducing hospitalization needs.

• Hospitals: Dominant due to complex case management and reimbursement structures.
• ASCs: Rapid adoption driven by outpatient-friendly device designs and cost efficiencies.
• Diagnostic Laboratories: Emerging as fast-growing end-users for histopathological analysis.

North America and Asia-Pacific: Regional Growth Frontiers

North America's market leadership is anchored in a well-established healthcare infrastructure, high CVD prevalence, and the presence of key OEMs investing in R&D. The U.S. alone accounted for a significant share, with USD 134.0 million in 2024, projected to reach USD 225.97 million by 2032 at a 6.77% CAGR. Reimbursement coverage and clinical guidelines bolster procedural volumes.

Asia-Pacific is the fastest-growing region, forecast at a 10.0% CAGR, led by China's rapid urbanization and rising healthcare spending. Improving infrastructure and awareness of early cardiac diagnosis are key catalysts. Europe follows with steady growth, supported by advanced diagnostic adoption and favorable regulatory frameworks.

Competitive Landscape and Supply Chain Intelligence

The market is characterized by the presence of diversified medical device manufacturers and specialized suppliers. Companies are focusing on precision engineering, imaging integration, and cost-effective solutions for emerging markets. Recent developments include:

• 2025: GODT reported a 6.8% global rise in heart transplants in 2024, boosting post-transplant monitoring demand.
• 2024: Approximately 60–65% of North American heart transplant patients underwent at least one EMB, per our primary research.
• 2025: CDC reported a 17% rise in U.S. myocarditis cases in 2024, driving a 12.5% increase in EMB procedures.

Supply chain dynamics reveal a concentrated OEM base for biopsy forceps, with key players in the U.S. and Europe. However, localization efforts in Asia-Pacific are intensifying, supported by government initiatives and cost pressures. Our trade flow analysis indicates growing imports of biopsy accessories into China and India, reflecting infrastructure build-out.

Personalized Medicine and Technological Disruption

The shift toward personalized medicine is a significant driver, as EMB enables tissue-level diagnostics for tailored treatment regimens in cardiomyopathy and transplant rejection. Technological advancements such as robotic-assisted biopsy systems, integration with echocardiography and MRI, and miniaturized forceps are enhancing procedural safety and diagnostic yield.

• Image-guided systems: Improve sampling accuracy and reduce complications.
• Robotic assistance: Emerging in select centers, promising precision and shorter procedure times.
• Molecular testing integration: Supports genetic and inflammatory profiling.

However, the invasive nature of EMB and the availability of non-invasive alternatives like cardiac MRI pose restraints. Our analysis suggests that minimally invasive and image-guided technologies will create lucrative opportunities, particularly in developed markets.

Regulatory and Reimbursement Framework Affecting Adoption

Regulatory support and clinical guidelines are critical enablers. In the U.S., reimbursement for EMB in transplant surveillance is well-established, while in Europe, varying country-level policies influence adoption. Asia-Pacific markets are witnessing evolving regulatory pathways, with China's NMPA streamlining approvals for advanced biopsy devices. Non-profit associations such as the International Society for Heart and Lung Transplantation (ISHLT) provide guidelines that bolster procedural standardization. Our primary interviews highlight that training and education programs for cardiologists are essential to bridge skill gaps, especially in emerging regions.